Phaseline

Targets › IFNG

IFNG (Interferon gamma): drug programs, companies and trials

15 programs from 14 companies in 15 trials: 10 Phase 2, 3 Phase 1, 2 Phase 3; Oncology, Infectious disease, Hematology; next expected readout Nov 2026.

Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation. Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation. (UniProt, P01579)

Open in Phaseline: the race on IFNG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hospices Civils de LyonInterferon gamma
Interferon gamma immunostimulatory cytokine
IFNGPhase 3Pneumonia, Ventilator-AssociatedJul 2027
University Hospital, LimogesInterferon Gamma 1-b
Interferon gamma cytokine for immune restoration in ICU-acquired immunosuppression
IFNGPhase 3Sustained ImmunosuppressionOct 2028
Hellenic Institute for the Study of SepsisEmapalumab-Izsg
Monoclonal antibody blocking interferon-gamma (IFNγ)
IFNGPhase 2SepsisNov 2026
Joseph OvedEmapalumab
Interferon gamma inhibitor
IFNGPhase 2Primary Immune Regulatory DisorderMar 2027
University of MiamiEmapalumab
Interferon gamma inhibitor
IFNGPhase 2DermatomyositisJul 2027
Marcela V. Maus, M.D.,Ph.D.Emapalumab
Interferon gamma inhibitor
IFNGPhase 2Large B-cell LymphomaAug 2027
Hefei Cancer Hospital of the Chinese Academy of SciencesInterferon-γ
Type II interferon cytokine
IFNGPhase 2Locally Advanced Esophageal Squamous Cell CarcinomaMar 2028
M.D. Anderson Cancer CenterEmapalumab
Interferon gamma inhibitor
IFNGPhase 2CytopeniaAug 2028
Assistance Publique - Hôpitaux de ParisInterferon Gamma 1-b
Interferon gamma-1b, recombinant interferon gamma therapy
IFNGPhase 2Post-aggressive ImmunosuppressionMar 2029
Stamford PharmaceuticalsSP-002
Replication deficient adenovirus-5 encoding human interferon gamma (IFNγ)
IFNGPhase 2Basal Cell CarcinomaMar 2029
Memorial Sloan Kettering Cancer CenterEmapalumab
Interferon gamma inhibitor
IFNGPhase 2Aplastic AnemiaMay 2029
National Institute of Allergy and Infectious Diseases (NIAID)Emapalumab
Interferon gamma inhibitor
IFNGPhase 2Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy EnteritisMar 2031
City of Hope Medical CenterEmapalumab
Interferon gamma inhibitor
IFNGPhase 1Acute Myeloid LeukemiaMay 2027
Nerissa T. Viola[89Zr]Zr-DFO-emapalumab
Interferon-gamma (IFN-γ) PET imaging agent - radiolabeled anti-IFN-γ antibody
IFNGPhase 1Non Small Cell Lung CancerJun 2028
National Institute of Allergy and Infectious Diseases (NIAID)Emapalumab-Izsg
Interferon gamma blocking antibody
IFNGPhase 1Chronic Granulomatous DiseaseDec 2032

Conditions

Acute Myeloid Leukemia (1) Aplastic Anemia (1) Cytopenia (1) Locally Advanced Esophageal Squamous Cell Carcinoma (1) Large B-cell Lymphoma (1) Basal Cell Carcinoma (1) Post-aggressive Immunosuppression (1) Chronic Granulomatous Disease (1) Pneumonia, Ventilator-Associated (1) Dermatomyositis (1) Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis (1) Primary Immune Regulatory Disorder (1)

Modalities

antibody (6), mixed (5), protein or peptide (3), small molecule (1)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (2) City of Hope Medical Center (1) Memorial Sloan Kettering Cancer Center (1) M.D. Anderson Cancer Center (1) Hefei Cancer Hospital of the Chinese Academy of Sciences (1) Marcela V. Maus, M.D.,Ph.D. (1) Stamford Pharmaceuticals (1) Assistance Publique - Hôpitaux de Paris (1) Hospices Civils de Lyon (1) University of Miami (1) Joseph Oved (1) University Hospital, Limoges (1) Nerissa T. Viola (1) Hellenic Institute for the Study of Sepsis (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.